Randy Prescilla

Feb 2, 2024 | onlinelibrary.wiley.com | Elaine Siegfried |Lara Lee |Jonathan M. Spergel |Randy Prescilla

1 INTRODUCTION Dupilumab is a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, as an immunomodulator. Current regulatory labeling recommends completing all age-appropriate immunizations before initiating dupilumab treatment and avoiding live vaccine administration during treatment.1, 2 The LIBERTY AD PRESCHOOL (Part A and B; NCT03346434) study prohibited live attenuated vaccine administration within 4 weeks before the baseline visit and during treatment.